BACKGROUND: A few recent studies have suggested that other sexually transmitted infections may increase the likelihood of a human papillomavirus (HPV) infection progressing to high-grade cervical neoplasia and cancer. GOAL: The goal was to assess whether exposures to Chlamydia trachomatis, human T-cell lymphotrophic virus type 1 (HTLV-I), and/or human simplex virus type 2 (HSV-2) are greater in colposcopy patients with cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) than in patients with low-grade cervical neoplasia (CIN1). STUDY DESIGN: Sequential patients (n=447) attending a colposcopy clinic in Kingston, Jamaica, a country with high cervical cancer rates and high HTLV-I prevalence, were tested for (1) HPV DNA by L1 consensus primer (MY09/11) polymerase chain reaction assays, (2) C trachomatis DNA by ligase chain reaction, (3) C trachomatis antibodies by both microimmunofluorescence and a peptide (VS4) enzyme linked immunosorbent assay (ELISA), (4) HTLV-I antibodies by ELISA confirmed by western blotting, and (5) HSV-2 antibodies by a recombinant HSV-2-specific ELISA. Odds ratios and 95% confidence intervals were estimated with use of multinomial logistic regression models. RESULTS: HPV DNA detection was associated with grade of cervical neoplasia but other evaluated sexually transmitted infections were not. CONCLUSIONS: HTLV-I, C trachomatis, and/or HSV-2 were not associated with severity of cervical neoplasia in Jamaican women.
BACKGROUND: A few recent studies have suggested that other sexually transmitted infections may increase the likelihood of a humanpapillomavirus (HPV) infection progressing to high-grade cervical neoplasia and cancer. GOAL: The goal was to assess whether exposures to Chlamydia trachomatis, human T-cell lymphotrophic virus type 1 (HTLV-I), and/or human simplex virus type 2 (HSV-2) are greater in colposcopy patients with cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) than in patients with low-grade cervical neoplasia (CIN1). STUDY DESIGN: Sequential patients (n=447) attending a colposcopy clinic in Kingston, Jamaica, a country with high cervical cancer rates and high HTLV-I prevalence, were tested for (1) HPV DNA by L1 consensus primer (MY09/11) polymerase chain reaction assays, (2) C trachomatis DNA by ligase chain reaction, (3) C trachomatis antibodies by both microimmunofluorescence and a peptide (VS4) enzyme linked immunosorbent assay (ELISA), (4) HTLV-I antibodies by ELISA confirmed by western blotting, and (5) HSV-2 antibodies by a recombinant HSV-2-specific ELISA. Odds ratios and 95% confidence intervals were estimated with use of multinomial logistic regression models. RESULTS:HPV DNA detection was associated with grade of cervical neoplasia but other evaluated sexually transmitted infections were not. CONCLUSIONS:HTLV-I, C trachomatis, and/or HSV-2 were not associated with severity of cervical neoplasia in Jamaican women.
Authors: Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk Journal: J Natl Cancer Inst Date: 2010-11-23 Impact factor: 13.506
Authors: Catharina Johanna Alberts; Maarten F Schim van der Loeff; Mary R Papenfuss; Roberto José Carvalho da Silva; Luisa Lina Villa; Eduardo Lazcano-Ponce; Alan G Nyitray; Anna R Giuliano Journal: Sex Transm Dis Date: 2013-06 Impact factor: 2.830
Authors: Magaly M Blas; Isaac E Alva; Patricia J Garcia; Cesar Carcamo; Silvia M Montano; Ricardo Muñante; Joseph R Zunt Journal: PLoS One Date: 2012-08-29 Impact factor: 3.240
Authors: Neerja Bhatla; Kriti Puri; Elizabeth Joseph; Alka Kriplani; Venkateswaran K Iyer; V Sreenivas Journal: Indian J Med Res Date: 2013-03 Impact factor: 2.375
Authors: Xiaotong He; Innocent O Maranga; Anthony W Oliver; Peter Gichangi; Lynne Hampson; Ian N Hampson Journal: Viruses Date: 2016-09-05 Impact factor: 5.048